Provide feedbackProvide feedback

Home :: Psychiatry :: Psychiatry Conferences :: APSS SLEEP 2007

Associated Professional Sleep Societies

APSS SLEEP 2007

June 9-14, 2007Minneapolis, MN
VerusMed is an independent news organization and is not affiliated with the Associated Professional Sleep Societies

Treating insomnia in older adults requires special consideration, sleep experts agree

Wednesday, December 12, 2007 | Comments

Clinicians should consider the unique epidemiology of insomnia in older adults and tailor treatments accordingly, a panel of experts said.

As the U.S. population continues to age, more and more older adults are likely to visit a sleep clinic, sleep lab, or other health care provider seeking treatment for insomnia. Dr. ...[more] Locked

Sublingual transmucosal zolpidem effective, well-tolerated among individuals with MOTN insomnia, findings show

Wednesday, December 12, 2007 | Comments

A low-dose buffered formulation of sublingual transmucosal (ST) zolpidem appears to improve sleep onset and duration among patients with insomnia characterized by middle-of-the-night (MOTN) awakenings, new findings indicate.

The double-blind, 3-way crossover study included 83 adults with primary insomnia and a history of ...[more] Locked

Low-dose doxepin improves wake after sleep onset among individuals with primary insomnia, data indicate

Wednesday, December 12, 2007 | Comments

The investigational insomnia agent doxepin improves wake after sleep onset (WASO) in people with primary insomnia, according to study findings. Additional findings suggest the improvement in WASO observed after 1 night of treatment is sustained after >=1 month of treatment.

During the trial, adults who had primary ...[more] Locked

Ramelteon does not impair stability, balance at peak plasma levels, findings show

Wednesday, December 12, 2007 | Comments

Ramelteon does not adversely affect stability or balance at near peak plasma levels in adults with chronic insomnia, suggest findings from a double-blind study.

A total of 275 adults with chronic insomnia (>=3 months) were included in the study. All participants received single-blind treatment with placebo during 2 ...[more] Locked

CBT plus zolpidem leads to greater increase in TST during initial short-term treatment relative to CBT alone, study indicates; subsequent discontinuation of zolpidem may enhance long-term outcomes

Wednesday, December 12, 2007 | Comments

In patients with persistent primary insomnia, a combination of cognitive behavioral therapy (CBT) and zolpidem for a short-term initial treatment period appears to yield greater increases in total sleep time (TST) relative to treatment with CBT alone, based on research supported by the National ...[more] Locked

Circadian rhythms: Time, temperature, thinking

Wednesday, December 12, 2007 | Comments

The Swiss researcher, Anna Wirz-Justice, Ph.D., was among the invited lecturers at the annual APSS meeting in Minneapolis. She is a professor emeritus at the Center for Chronobiology of the Psychiatric University Clinics in Basel. For several decades, Wirz-Justice has been a key figure ...[more] Locked

New research offers insight into pathophysiology of insomnia, potential targets for treatment

Wednesday, December 12, 2007 | Comments

Advances in preclinical and clinical research have expanded what is known about the pathophysiology of insomnia and potential targets for treatment, according to a panel of experts.

Dr. Clifford Saper, chairman of the department of neurology at Beth Israel ...[more] Locked

Patients with insomnia, comorbid depression have more severe insomnia at baseline relative to patients with primary insomnia, other comorbidities

Wednesday, December 12, 2007 | Comments

Patients with insomnia and comorbid major depressive disorder appear to have the most severe nighttime and daytime symptoms at baseline as compared with patients who have primary insomnia (PI) or patients who have insomnia with comorbid generalized anxiety disorder, perimenopausal transition (PMT), or rheumatoid arthritis, new ...[more] Locked

Investigational melatonin agonist improves sleep onset, maintenance in model of transient insomnia

Wednesday, December 12, 2007 | Comments

The investigational MT1/MT2 receptor agonist, VEC-162, improves measures of sleep onset and maintenance, suggest findings from a Phase III trial that used a model of transient insomnia to evaluate the drug's efficacy in adults with otherwise normal sleep.

Thomas Roth, head of the Henry ...[more] Locked

Eszopiclone demonstrates moderate to strong effect sizes on sleep outcomes relative to placebo in patients with primary insomnia, insomnia with comorbidities

Wednesday, December 12, 2007 | Comments

Eszopiclone therapy appears to provide moderate to strong effects on a number of outcome measures among patients with primary insomnia (PI) and patients who have insomnia with comorbid major depressive disorder, generalized anxiety disorder, perimenopausal transition (PMT), or rheumatoid arthritis, with the largest effects observed ...[more] Locked

Insomnia represents potentially large financial liability for employers, research indicates

Wednesday, December 12, 2007 | Comments

Employees with insomnia appear to incur higher health benefit costs relative to employees without insomnia, results from a retrospective analysis show.

"Because people with insomnia have a number of comorbities, it's hard to look at the true cost of insomnia," lead researcher Richard Brook, of ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos